Danaher DHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $7.48B+2.5% | $7.29B+2.3% | $7.13B+2.1% | $6.98B+2.0% | $6.85B+1.3% | |
| Diagnostics | $9.91B-0.3% | $9.94B+0.8% | $9.86B+1.0% | $9.76B+0.5% | $9.71B-0.8% | |
| Life Sciences | $7.39B+0.8% | $7.33B+0.7% | $7.28B+0.1% | $7.27B+0.1% | $7.26B-0.9% | |
| Segment Reporting, Other Segment Item, Amount by Business | ||||||
| Biotechnology | $4.36B+1.5% | $4.29B+2.7% | $4.18B+2.0% | $4.1B+1.3% | $4.05B-0.4% | |
| Diagnostics | $6.69B+0.1% | $6.68B+0.5% | $6.65B+0.5% | $6.62B+0.8% | $6.56B+0.5% | |
| Life Sciences | $5.61B+0.5% | $5.58B+1.3% | $5.51B+0.6% | $5.47B+0.6% | $5.44B-0.8% | |
| Operating Income (Loss) by Business | ||||||
| Biotechnology | $1.96B+5.0% | $1.86B+1.7% | $1.83B-2.0% | $1.87B+3.8% | $1.8B+6.9% | |
| Diagnostics | $2.61B-1.7% | $2.65B+3.5% | $2.56B+2.0% | $2.51B-0.1% | $2.51B-4.3% | |
| Life Sciences | $544M+4.6% | $520M-7.1% | $560M+50.1% | $373M-55.9% | $845M-3.9% | |
| Identifiable assets by Business | ||||||
| Biotechnology | $148.89B+0.4% | $148.32B+1.9% | $145.58B— | —— | —— | |
| Depreciation by Business | ||||||
| Biotechnology | $155M+4.0% | $149M+0.7% | $148M+1.4% | $146M+2.1% | $143M-5.3% | |
| Diagnostics | $409M+0.5% | $407M+1.0% | $403M+1.5% | $397M0.0% | $397M+0.8% | |
| Life Sciences | $188M+1.6% | $185M+2.2% | $181M+1.7% | $178M+2.3% | $174M+4.2% | |
| Capital expenditures, gross by Business | ||||||
| Biotechnology | $353M-4.6% | $370M-0.5% | $372M-5.8% | $395M-7.3% | $426M-4.7% | |
| Diagnostics | $621M+4.9% | $592M+4.8% | $565M+5.2% | $537M-0.2% | $538M-2.2% | |
| Life Sciences | $165M-11.3% | $186M-48.0% | $358M-3.2% | $370M-2.4% | $379M-3.1% | |
| Intangible Amortization by Business | ||||||
| Biotechnology | $923M+2.3% | $902M+1.9% | $885M+1.5% | $872M+1.6% | $858M-0.6% | |
| Diagnostics | $191M0.0% | $191M0.0% | $191M-0.5% | $192M0.0% | $192M0.0% | |
| Life Sciences | $607M+0.5% | $604M+0.5% | $601M+1.2% | $594M+1.7% | $584M+1.4% | |
| Goodwill by Business | ||||||
| Biotechnology | $92.6B+0.7% | $91.91B+2.1% | $90.04B+0.7% | $89.42B+1.4% | $88.16B+0.5% | |
| Diagnostics | $27.88B+0.4% | $27.76B+0.8% | $27.53B+0.1% | $27.5B+0.5% | $27.36B0.0% | |
| Life Sciences | $51.38B+0.6% | $51.08B+1.1% | $50.53B+0.3% | $50.4B+1.6% | $49.61B+0.8% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $4.44B-0.1% | $4.44B+1.9% | $4.36B+0.3% | $4.35B-2.0% | $4.43B-1.7% | |
| Recurring revenue | $20.34B+1.1% | $20.13B+1.1% | $19.91B+1.2% | $19.67B+1.4% | $19.39B+0.1% | |
| Sales by Geography | ||||||
| High-growth markets | $7.11B+1.2% | $7.02B+1.6% | $6.91B+0.6% | $6.87B0.0% | $6.87B0.0% | |
| North America | $10.25B-1.0% | $10.36B-0.2% | $10.37B+1.2% | $10.25B0.0% | $10.25B-0.5% | |
| Other developed markets | $1.26B+0.5% | $1.25B+0.4% | $1.25B+1.4% | $1.23B+0.2% | $1.23B-2.0% | |
| Western Europe | $6.16B+3.7% | $5.94B+3.5% | $5.74B+1.3% | $5.66B+3.4% | $5.48B+0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
